Why Are Millions Turning to Peptides, and Can Regulators Keep Up With Demand?

In this interview with Impact Newswire, Jeff Cohen, attorney for BioLongevity Labs and co-founder of the American Peptide Association, argues that the surge in global peptide demand reflects a broader cultural shift in how consumers approach healthcare. He feels that confidence in traditional medical systems weakened after COVID-19, prompting more individuals to take personal responsibility for their wellness decisions and seek out alternative or adjacent therapies, including peptides. This shift, he believes, has helped move peptides from specialist clinical use into mainstream consumer health, particularly in areas such as weight loss, hormone optimization, and anti-aging. He says the rise of GLP-1 drugs, including semaglutide and tirzepatide, has accelerated this transition by demonstrating strong and rapid outcomes in obesity treatment, which in turn has driven broader interest in peptide-based therapies.

Peptides are moving from specialist clinical use into mainstream consumer health, driven by strong demand for weight loss, anti-aging, and hormone therapies. The shift is most visible in the rapid expansion of GLP-1 based treatments such as semaglutide and tirzepatide, which have reshaped both pharmaceutical markets and adjacent wellness industries.

Market data underscores the scale of growth. The global peptide therapeutics market is estimated at about $140.9 billion in 2025 and is projected to reach roughly $294.6 billion by 2033, reflecting compound annual growth of around 8.7 percent as obesity and metabolic disease rates rise globally. 

Within this, GLP-1 drugs are the dominant growth engine. The global market for GLP-1 receptor agonists used in weight management is projected to rise from about 13.8 billion dollars in 2024 to nearly 48.8 billion dollars by 2030, representing annual growth of roughly 18.5 percent (Grand View Research). This surge in demand has also fuelled rapid expansion in telehealth prescribing, compounding pharmacies, and direct-to-consumer wellness platforms offering peptide-based therapies.

Regulatory pressure is increasing alongside this growth. The U.S. Food and Drug Administration has stepped up scrutiny of compounded GLP-1 products, issuing warning letters to telehealth firms over marketing claims that suggest compounded semaglutide products are equivalent to FDA-approved drugs. The agency has also signalled tighter oversight of compounding practices, particularly where blockbuster obesity treatments are involved, citing concerns around safety, consistency, and consumer misinformation.

At the same time, the FDA is reviewing whether to expand access to certain previously restricted peptides, a move that could broaden clinical availability but also reshape the boundaries between approved drugs, compounded formulations, and research-use products.

This has created a fast-moving and often confusing landscape for consumers. Demand for peptide therapies is rising, but regulatory definitions remain uneven across jurisdictions and delivery channels. Industry participants say this gap has opened space for unregulated or poorly understood products sold online, alongside legitimate FDA-approved therapies and pharmacy-compounded versions.

Against this backdrop, legal and regulatory specialists argue that the central issue is clarity. The key questions are what qualifies as an approved medicine, what can be legally compounded under current FDA rules, and what consumers should understand before using peptide-based therapies sourced outside traditional medical channels.Editor Faustine Ngila spoke with Jeff Cohen, Attorney for BioLongevity Labs andPresident, American Peptide Association. Here is the full interview:

1. Peptides appear to have moved from a niche biohacking trend into mainstream healthcare. What has changed over the last two years to drive this surge in consumer demand?

The cultural impact of COVD caused the public to lose confidence in healthcare and political leaders.  That caused the public to take even more responsibility for their own wellness objectives.     

Human curiosity in wellness has traditionally been somewhat dampened by the authoritarian nature of how healthcare has been delivered.  Citizens would historically wait for healthcare leaders to achieve consensus and then lead.  COVID eroded that dynamic.     

At the same time, the information environment changed as the internet became flooded with reports of failing American health and wellness fixes. The gap between what traditional healthcare leaders could agree on and the public’s willingness to explore and search for even just anecdotal outcomes grew.  

It’s pure pattern recognition, but on a mass cultural basis.  It became impossible to ignore failed promises in critical areas like obesity, chronic metabolic issues, inflammation, and performance decline. When the standard options don’t work, people look for what does.

The mainstream didn’t discover peptides. The public (including many disillusioned clinicians) leapfrogged over the failure of traditional consensus based healthcare and demanded outcomes they actually experience with peptides.  

2. The global peptide therapeutics market was valued at roughly $141 billion in 2025 and is projected to nearly double by 2033, while GLP-1 drugs have become one of the fastest-growing pharmaceutical categories worldwide. To what extent is the success of drugs like semaglutide and tirzepatide driving broader interest in peptides? 

Enormously!  Semaglutide and tirzepatide hit our obesity laden culture right in the face.  This was truly a Holy Grail moment for wellness in our culture.  Remarkable and fast outcomes with GLPs paved the way for consumers to flood the entire peptide landscape.  Peptide-based therapies produced fast, real, measurable outcomes where other interventions had largely failed. That powerful proof of concept made consumers curious about the broader category.

But here’s what doesn’t get discussed enough: Pharma captured the upside and then set the terms of the conversation. Pharma’s financial interest in the GLP slice of the peptide pie is driving a wedge between supply and the growing public demand for peptides.  Pharma’s message in the GLP space of “Our stuff is safe and good and competing products aren’t” is being integrated into state and federal regulations and the media driven narrative. What’s at risk is the entire peptide product offering.  Pharma’s seemingly legitimate focus on safety and quality has the primary effect of protecting market position, not patients.  And ironically much of what’s being promoted by regulators (e.g., domestic vs international source of product) has no bearing at all on the issue of safety or quality.  

The interest GLP-1s generated is fantastic for wellness and the peptide industry. How that interest is being channeled and controlled by Pharma, which is the only “player” with ties to regulators and journalists, is where we have to focus and take leadership.

3. Many consumers now associate peptides almost exclusively with weight loss. What are the most promising non-obesity applications currently being researched, and where are we seeing the strongest clinical evidence?

The peptide/weight loss association is understandable given the media attention, but it misses the full spectrum of dramatic peptide based applications.  

The strongest evidence outside metabolic health: BPC-157 in tissue repair and gut integrity, thymosin-based peptides in immune modulation, Semax and Selank in cognitive function and neuroprotection. Decades of Eastern European clinical research far outpaces Western medicine research.  PT-141 has FDA approval for hypoactive sexual desire disorder in women, which most people don’t even know!  It lacks the Pharma driven media machine and so lives more in the shadows.  

The most interesting work in this space has nothing to do with weight loss. It’s about the body’s ability to repair, regulate, and maintain itself at a level for which conventional medicine doesn’t really have tools. That’s where the attention should be going and is in fact going.  Simply put, the future of American wellness belong to longevity.  And peptides will have a home there for many years to come!

4. The FDA has tightened oversight of compounded GLP-1 products as shortages ease and more branded products become available. How is this changing the peptide market, and what should patients understand about the difference between FDA-approved drugs and compounded therapies? 

When semaglutide was on the shortage list, compounding pharmacies and non pharmacy manufacturers were asked to produce it.  And they did just that for over two years without a single disapproving word from the FDA, any state regulator or the media!  With non Pharma manufacturers activated, patients got access to a therapy that worked at a fraction of the Pharma cost. 

When the shortage was declared in the Fall of 2024 by FDA (in private consultation with Eli Lily and Novo Nordisc) to be over two and a half years later, the entire non Pharma manufacturing space began to be sued and vilified. 

Pharma has been brilliant in maligning an entire manufacturing and distribution industry in the peptide space.  Phrases like “research chemicals” and “not FDA approved” have been weaponized by Pharma and are quickly being adopted by both regulators and the media as meaning unsafe and ineffective.  There is no such thing, legally speaking, as a “research chemical.”  And all compounded medications for decades have been “not FDA approved.”

Patients and even clinicians need to understand: “FDA-approved” and “safe and effective” are not synonyms. If that were true, there would be no recalls, fines and class action lawsuits against Pharma.  Even more, patients and clinicians need to understand that the fact that many peptides are made by non pharmacy sources does not mean unsafe or ineffective.  If that was true, there would be no FDA 483 deficiency reports applicable to compound pharmacies.  

FDA approval means a specific product went through a specific process. It doesn’t mean compounded versions of the same molecule are dangerous. Many compounding pharmacies and non pharmacy manufacturers operate with rigorous quality standards. The molecule doesn’t change because of the label on the vial.  And it doesn’t change based on the country from which it originates. 

5. There have been reports that regulators are reviewing access to several peptides that were previously restricted for compounding. What is actually happening from a regulatory standpoint, and where do you see the landscape heading over the next 12 months? 

The entire direct to consumer peptide industry is under attack by Pharma, the FDA and the media.  Why?  Because they dared to carry GLPs that compete with Pharma (after the FDA invited them to fix the shortage issue).  If there were no GLPs in the direct to consumer peptide space, no one would have heard anything about the fabricated term “research chemicals.”  

That said, there is good news afoot.  At least a dozen peptides are set to consideration to move to an approved chemical list.  While that doesn’t matter to consumers, it matters a lot to clinicians concerned about risking their licenses.  And clinician based peptide platforms are growing every day.  

What I expect over the next 12 months: continued pressure by Pharma to protect their investment in GLPs, continued growth of clinician led peptide and functional wellness and emergence of the peptide industry (e.g., the American Peptide Association) as leaders in the consumer wellness safety, efficacy and access. 

6. A growing number of websites market peptides directly to consumers, often with minimal oversight. What are the biggest misconceptions people have when purchasing peptide products online?

The biggest one is that the “research” or “RUO” label means the product is for lab animals, is unsafe or poor quality or legally problematic.  Long story short–that label was adopted on the advice of regulatory counsel to create a defensible position with the FDA. It has nothing at all to do with safety, quality or (usually) even research.  

The second one is that country of origin equates to safety or quality.  There is nothing at all that supports that.  

The third is the only viable substitute for a Pharma manufactured drug is a compound pharmacy.  Wrong.  If any of what Pharma is selling regulaltors and the media on the safety and quality issue was true, there would be no fines, settlements, class actions in the Pharma arena and there would be no FDA 483 deficiency reports for licensed compound pharmacies.   

Until the issues of safety, quality and access are brought to a properly staffed “table” with key opinion leaders in the peptide space, the false narrative will continue to be created and propagated by Pharma.  The truth is that the peptide industry is a human enterprise.  Which means some manufacturers are great and some are not.  But they do not divide by country of origin, nature of the label or even the type of manufacturer.  Still, it is on the peptide industry to take leadership to define and agree on what constitutes a safe and effective product.  That’s an APA deliverable for 2026!

7. How significant is the problem of counterfeit, mislabeled, or low-quality peptide products, and what red flags should consumers watch for before purchasing or using these therapies?

It’s significant. And the variable isn’t geography. That’s a narrative Pharma has worked hard to promote. There are excellent manufacturers overseas and bad actors domestically. Location is not the issue. Integrity is.  And Pharma is right to insist on agreement and uniformity on what constitutes safety and quality.  

The baseline of safety and quality is third-party testing. If a company can’t produce a certificate of analysis from an independent lab and also show purity, potency, and absence of contaminants, walk away. That’s not a yellow flag — it’s a red one.

Other signals include vague sourcing, no verifiable manufacturing information, pricing that doesn’t make economic sense. Legitimate operators are not defensive about their quality standards. They’re transparent and proud of them.

8. Critics argue that consumer enthusiasm for peptides has outpaced the scientific evidence. Which peptide therapies have the strongest clinical backing today, and which are receiving more attention than the data currently supports?

Strongest backing: GLP-1 receptor agonists. The data is extensive and the mechanism well understood. PT-141 has FDA approval. Thymosin alpha-1 has decades of clinical study in immune function. BPC-157 has a robust preclinical base and consistent practitioner outcomes, though large-scale human RCTs are still limited.

Where enthusiasm is running ahead: some newer peptide combinations marketed for cognitive enhancement and anti-aging are moving faster than the evidence currently supports. That doesn’t mean they’re ineffective. It means we’re in a period where outcomes are being observed before the trials catch up. That happens in medicine.

Read the criticism. But also consider who’s funding it. Both things matter.

9. The World Health Organization has raised concerns about unequal access and the spread of falsified GLP-1 products globally. Do you believe the peptide industry is prepared for the scale of demand it is now facing? 

Honestly? Not yet. And the industry needs to be clear-eyed about that.

The scale GLP-1s created exposed infrastructure gaps that were always there but never stress-tested at this level. Supply chains, quality assurance, clinical oversight, regulatory compliance — all of it must be beefed up and scaled to ensure safety and quality in face of rocketing consumer and clinician demand.

The operators who built with integrity based structure are positioned to scale. The ones who built fast and loose focused entirely on sales volumes are not.  This industry has work to do with standards, testing protocols, supply chain transparency, practitioner education. These set up the foundation that ensure this industry is credible at scale and most importantly that consumers continue to have access at reasonable prices.

The demand is here and growing every day.  It’s not going away.  This industry will self-regulate or will continue to be targeted with imprecise and unnecessary regulation and bad press that does nothing for safety and quality and serves only to protect Pharma’s interest in GLPs.

Stay ahead of the stories shaping our world. Subscribe to Impact Newswire for timely, curated insights on global tech, business, and innovation all in one place.

Dive deeper into the future with the Cause Effect 4.0 Podcast, where we explore the ideas, trends, and technologies driving the global AI conversation.

Got a story to share? Pitch it to us at info@impactnews-wire.com and reach the right audience worldwide